Ebola vaccine trial suspended after side effects

Image
AP London
Last Updated : Dec 11 2014 | 9:05 PM IST
Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.
In a statement issued today, the Hopitaux Universitaires de Geneve said the trial had been suspended "as a precautionary measure." The study involving 59 people began in November.
Researchers reported four cases of mild joint pain in the hands and feet in people who got the shot 10 to 15 days earlier. Officials will stop giving the vaccine next week to get more data and liaise with others who are testing the vaccine in the US, Canada, Germany and Gabon.
The vaccine was developed by the Canadian government and is licensed to two US companies, NewLink and Merck The trial is scheduled to resume in January in Geneva.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 11 2014 | 9:05 PM IST

Next Story